20th April, London, UK: Phynova attended the 1st UK-India Bioconclave conference that brought together business leaders, policy makers, innovators, academics, entrepreneurs, investors and distributors from the UK and India on the same platform to exchange ideas, build relationships and forge future partnerships.
Representatives form the UK included Professor Sir Malcolm Grant, Chairman, NHS and Patricia Hewitt, Chair, UK India Business Council (UKIBC).
The dominating theme discussed by both parts of the world was the need to tackle growing numbers of diabetics and childhood obesity. The conditions bore a deep hole in the NHS fund every year wherein diabetes itself amounts to £1.5m an hour or 10% of the NHS budget for England and Wales. In India, Diabetes is a potential epidemic with 67 million affected people and has significantly increased the morbidity, mortality and financial burden on a resource limited country.
It was suggested that the NHS was looking forward to innovation in the healthcare delivery model with a focus on preventative healthcare, ideal for chronic lifestyle diseases such as Type II Diabetes. The talk on investment opportunities in India highlighted that management of Diabetes was certainly a promising area for bilateral ties.
Reducose® manages healthy blood glucose levels and holds applications in consumer healthcare and FMCG sectors. Preventative healthcare solutions start with lifestyle management focusing on healthy foods and exercise.
Watch the day unfold at here.
Reducose® is a patented natural functional ingredient that transforms products with high levels of sugar or poor-quality carbohydrates into ‘better for you’ products. It is a sustaining innovation that allows food companies to continue to use sugar without having to reformulate, while at the same time mitigating harmful side effects.
About Glycaemic Index
The Glycaemic Index ranking system indicates how quickly a carbohydrate food raises blood glucose. Generally, the more processed a food, the higher its Glycaemic Index. Decreasing the GI of the diet may improve insulin sensitivity and reduce the risk for metabolic diseases such as obesity and type-2 diabetes. Eating a lower-GI diet may also decrease the risk for complications in those previously diagnosed with diabetes.
About EPG Bioconclave
The inaugural bioConclave 2015 is an initiative by EPG Strategic Communications (UK) to creating closer collaborations between Indian and European Life Sciences companies.